Results 1 to 10 of about 49,715 (213)
Janus kinase inhibitors: jackpot or potluck?
Oncology Reviews, 2012 The reports of a unique mutation in the Janus kinase-2 gene (JAK2) in polycythemia vera by several independent groups in 2005 quickly spurred the development of the Janus kinase inhibitors.
Pavithran Keechilat +1 more
doaj +3 more sources
Treatment response to Janus kinase inhibitor in a child affected by Aicardi‐Goutières syndrome [PDF]
Clinical Case Reports, 2023 Key Clinical Message Baricitinib, a Janus kinase inhibitor (JAK‐inhibitor), seems to contribute to an improvement of a child affected by Aicardi‐Goutières syndrome (AGS), reducing the interferon score and determining a recovery of cognitive ...
Jessica Galli +8 more
doaj +2 more sources
Janus kinase inhibitor audit [PDF]
Clin Med (Lond), 2023 Beck J, Banford S.
europepmc +3 more sources
The Upadacitinib - New Janus Kinase Inhibitor - Literature Review
Quality in SportAtopic dermatitis (AD) is a chronic, recurrent dermatosis that affects an increasing percentage of the population. It usually affects children and resolves spontaneously, however, symptoms can persist into adulthood and even appear de novo later in life.
Michalina Grzelka +9 more
doaj +2 more sources
Janus Kinase Inhibitors and Cell Therapy [PDF]
Frontiers in Immunology, 2021 Cellular therapies such as allogeneic hematopoietic stem cell transplantation (HSCT) and immune-effector cell therapy (IECT) continue to have a critical role in the treatment of patients with high risk malignancies and hematologic conditions. These therapies are also associated with inflammatory conditions such as graft-versus-host disease (GVHD) and ...
Amer Assal +2 more
openaire +3 more sources
Immunological Medicine, 2023 Recent studies have gradually elucidated the pathogenesis of inflammatory bowel disease; thus, the Janus kinase (JAK)-signal transducers and activators of transcription pathway are strongly involved in the pathophysiology of inflammatory bowel disease ...
Hiroshi Nakase
doaj +1 more source
Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor [PDF]
JAAD Case Reports, 2023 Carine M. Lama, MS +4 more
doaj +2 more sources
The use of Tofacitinib in the treatment of inflammatory bowel disease [PDF]
Терапевтический архив, 2019 Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus ...
E L Nasonov +2 more
doaj +1 more source
Peripheral neuropathy associated with tofacitinib use in alopecia universalis
Journal of Dermatology and Dermatologic Surgery, 2022 Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. Alopecia universalis (AU) is the advanced form of AA characterized by complete scalp and body hair loss.
Raghad Alharthi +4 more
doaj +1 more source
BMC Infectious Diseases, 2021 Background The spread of a highly pathogenic, novel coronavirus (SARS-CoV-2) has emerged as a once-in-a-century pandemic, having already infected over 63 million people worldwide. Novel therapies are urgently needed.
Lucas Walz +6 more
doaj +1 more source